The major goals of this proposal are to identify and define virus and host factors important to the pathogenesis of AIDS. Of particular emphasis in the next project period will be an elucidation of the interactions between human cytomegalovirus (CMV) and human immunodeficiency virus type I (HIV-1) in the natural history and AIDS development and progression. There is substantial evidence that the vast majority of patients with AIDS are infected with both viruses. Interactions may take several forms (a) additive or synergistic immunosuppression or cytopathology (b) activation of one virus by the other (c) alteration of cell surface receptors to one virus by infection with the other (d) phenotypic mixing (e) viral recombination. CMV-HIV-1 interactions in vitro and in vivo will be explored. Cells dually infected will be studied for progeny CMV/HIV pseudotypes or recombinants by a variety of techniques including cross-neutralization, immune electron microscopy, and altered tropism determinations. Attempts will be made to rescue an envelope-deficient HIV-1 molecular construct from cells carrying it by use of a CMV envelope. Rescue analysis will be assessed by use of selective markers (resistance to mycophenolic acid), polymerase chain reaction assays of secondarily infected fibroblasts, and detection of HIV-1 antigen expression. In addition, the mechanisms underlying CMV transactivation of HIV-1 expression will be evaluated. in vivo interactions between CMV and HIV-1 will also be explored. Dually infected patients will have specimens (blood, semen) examined for CMV/HIV pseudotypes or recombinants. Autopsy brain and retinal specimens will also be studied. The tropism of CMV/HIV pseudotypes or recombinants derived from these sources will be evaluated on endothelial cell targets, as will the expression of novel receptors on such cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA035020-10
Application #
3172781
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Project Start
1983-05-01
Project End
1994-04-30
Budget Start
1992-05-01
Budget End
1993-04-30
Support Year
10
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Margalith, M; D'Aquila, R T; Manion, D J et al. (1995) HIV-1 DNA in fibroblast cultures infected with urine from HIV-seropositive cytomegalovirus (CMV) excretors. Arch Virol 140:927-35
Schooley, R T (1995) HIV-1-specific cytotoxic T-cell responses. AIDS 9 Suppl A:S113-6
Rusconi, S; Merrill, D P; Hirsch, M S (1994) Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy. J Infect Dis 170:1361-6
Mazzulli, T; Rusconi, S; Merrill, D P et al. (1994) Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob Agents Chemother 38:656-61
Margalith, M; Medina, D J; Hsiung, G D et al. (1993) Interactions between HIV-1 and cytomegalovirus in human osteosarcoma cells carrying both viruses. AIDS Res Hum Retroviruses 9:519-27
Mazzulli, T; Rubin, R H; Ferraro, M J et al. (1993) Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in persons with AIDS. J Clin Microbiol 31:2824-7
Conway, B; Bechtel, L J; Adler, K A et al. (1992) Comparison of spot-blot and microtitre plate methods for the detection of HIV-1 PCR products. Mol Cell Probes 6:245-9
Johnson, V A; Merrill, D P; Chou, T C et al. (1992) Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis 166:1143-6
Eron Jr, J J; Johnson, V A; Merrill, D P et al. (1992) Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. Antimicrob Agents Chemother 36:1559-62
Johnson, V A; Merrill, D P; Videler, J A et al. (1991) Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis 164:646-55

Showing the most recent 10 out of 46 publications